

## **LIFESTYLE CHANGES IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW PROTOCOL**

### **AUTHORS:**

**Tiziana Fernández-Mincone**

**ORCID: 0000-0002-0865-9198**

**Departamento de Ciencias de la salud, Pontificia Universidad Católica de Chile, Santiago, Chile**

**Macarena Viñuela Morales**

**ORCID: 0000-0002-4433-3718**

**Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago de Chile**

**Marco Arrese Jiménez**

**ORCID 0000-0002-0499-4191**

**Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile.**

**Centro de Envejecimiento y Regeneración (CARE), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.**

**FONDECYT 1191145; CONICYT, AFB170005, CARE Chile UC**

**Juan Pablo Arab Verdugo**

**ORCID 0000-0002-8561-396X**

**Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile.**

**Centro de Envejecimiento y Regeneración (CARE), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.**

**FONDECYT 1200227**

**Daniel Cabrera**

**ORCID 0000-0002-9055-4191**

**Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile.**

**Facultad de Ciencias Médicas, Universidad Bernardo O Higgins, Santiago, Chile.**

**FONDECYT 11171001**

**Francisco Barrera Martínez**

**ORCID 0000-0001-5334-1528**

**Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile.**

**FONDECYT 1191183**

## Abstract

Non-alcoholic fatty liver disease (NAFLD) is a worldwide raising liver condition and it is expected to become the first cause of progression to cirrhosis and hepatocellular carcinoma in the next 5 years (Araújo 2018). At present, there are no pharmacological treatments approved. Weight loss is the first-line treatment (European Association for the Study of the Liver 2016) (Chalasanani 2012) showing that 7 to 10% weight loss improves steatosis, inflammation, hepatocyte ballooning and, in NASH patients, has an impact in fibrosis too (Romero-Gómez 2017). However, the reduction and maintenance of weight loss is often complex. To achieve this goal, it is recommended doing lifestyle changes including exercise and diet on daily living (Hannah 2016). However, it has been difficult to establish any conclusions regarding the best type of diet or exercise protocol to maximize improvements and to maintain its effects through time. Because of this, the objective of this review is assessing the efficacy and safety of diet, exercise, or a combination of these in patients with NAFLD.

## Introduction

Non-alcoholic fatty liver disease (NAFLD) is a condition that includes a spectrum of liver diseases ranging from simple steatosis, entity where lipid droplets accumulates within the cytoplasm in more than 5% of hepatocytes, to non-alcoholic steatohepatitis (NASH), characterized by steatosis, inflammation and hepatocyte cell ballooning associated with fibrosis (Arab 2018) (Malaguarnera 2009), not caused by other factors. It is strongly associated with obesity, insulin resistance (IR), type II Diabetes Mellitus (T2DM) and dyslipidemia (EASL-EASD-EASO 2016).

Its prevalence is 24-25% in general population and it is expected to become the first cause of progression to cirrhosis and hepatocellular carcinoma in the next 5 years (Araújo 2018).

Weight loss is the first-line treatment of non-alcoholic liver disease (European Association for the Study of the Liver 2016) (Chalasanani 2012). A 7 to 10% weight loss improves steatosis, inflammation, hepatocyte ballooning and, in NASH patients, has an impact in fibrosis too (Romero-Gómez 2017). However, the reduction and maintenance of weight loss is often complex

The strategies to achieve this goal are lifestyle changes which includes exercise and diet therapy (Hannah 2016). Exercise has a large effect in intrahepatic triglycerides, enzymes levels, insulin sensitivity, glucose homeostasis (Katsagoni 2017) (Kenneally 2017), free fat acids transportation and oxidation, radical of oxygen production and inflammation (van der Windt 2018). Current guidelines for management of NAFLD recommends 150 minutes per week of moderate exercise (Leoni 2018), similar to what American College of Sports Medicine indicates. About diet, it has been suggested that decreasing caloric intake between 750-1000 kcal/day or 30% of the intake, improves IR and hepatic steatosis (Chalasanani 2018) and its composition can reduce free fatty acids, fasting glucose, IR and alanine-transferase (Dongiovanni 2016). In combination, diet plus exercise have demonstrated improvements in liver histology, liver enzymes (Katzagoni 2017) and weight reductions of 4.2% to 10.6% (Thoma 2012).

There are several publications about lifestyle changes and NAFLD reduction (Wong 2013) (Younossi 2017) (Zou 2018). However, it has been difficult to establish any conclusions regarding the best type of diet or exercise protocol to maximize improvements and to maintain its effects through time.

## **Objectives**

To assess the efficacy and safety of diet, exercise, or a combination of these in patients with NAFLD.

## **Methods**

### **Criteria for considering studies for this review**

**Types of studies:** we will only include randomized clinical trials. Studies evaluating the effects on animal models or in vitro conditions will be excluded.

**Types of participants:** We will include trials assessing participants older than 18 years old with NAFLD, NASH or non-alcoholic cirrhosis. NAFLD should have been diagnosed based on abnormalities in laboratory test (Kemp 2008), liver biopsy, ecography, ultrasound (US) or magnetic resonance imaging (MRI). NASH and cirrhosis should have been diagnosed by liver biopsy or blood test or scores such as NAFLD fibrosis score or NAFLD activity score as international guidelines mentioned (Leoni 2018).

Studies that consider healthy volunteers, patients with other liver conditions such as hepatitis, vascular disorders, drugs or toxin induced liver injuries or alcoholic liver disease (Reisner 2015), metabolic syndrome, obesity or T2DM without NAFLD will be excluded.

**Types of interventions:** We will include any trial assessing the effect of lifestyle interventions, considering dietary and/or exercise interventions.

Dietary interventions are defined as any diet with calorie restriction, low fat or low carbohydrates composition. Exercise was defined by Caspersen (Caspersen 1985) as “physical activity that is planned, structured, repetitive, and purposive in the sense that improvement or maintenance of one or more components of physical fitness is an objective”. Physical fitness includes health-related components like cardiorespiratory endurance, muscular endurance, muscular strength, body composition, and flexibility (Caspersen 1985).

The comparison of interest will be conventional/standard/optimal treatment or no treatment, as defined by the authors of the trials.

### **Types of outcome measures**

We will not use outcomes as an inclusion criterion during the selection process. Any article meeting all the criteria except for the outcome criterion will be preliminarily included and assessed in full text.

a. **Primary outcomes:**

- ☐ Cardiovascular events
- ☐ All-cause mortality
- ☐ Quality of life

b. **Secondary outcomes:**

- ☐ Anthropometric measurements: lean body mass, BMI
- ☐ Physical fitness: maximum/peak oxygen

c. **Other outcomes:**

- ☐ Reversion of histological alterations such as steatosis, inflammation, fibrosis, liver cell injury
- ☐ Intrahepatic triglycerides
- ☐ Liver enzymes concentrations
- ☐ HbA1c, HOMA-IR, fasting glucose
- ☐ Lipid profile

**Search methods for identification of studies**

**Electronic searches**

We will search the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (latest issue), MEDLINE Ovid, Embase Ovid, LILACS, without any language or publication status restriction. The searches will cover from the inception date of each database until the day before submission.

**Other sources**

In order to identify articles that might have been missed in the electronic searches, we will search for primary studies in the following sources:

- Systematic reviews about NAFLD and lifestyle changes
- Online trial registries such as ClinicalTrials.gov ([clinicaltrials.gov](http://clinicaltrials.gov)) and WHO International Clinical Trial Registry Platform ([www.who.int/ictrp](http://www.who.int/ictrp)) for ongoing or unpublished trials.
- Google Scholar and Microsoft Academic for cross-citation search using each included study as the index reference.
- Reference lists of included studies to identify additional trials for inclusion.

## **Data collection and analysis**

### **Selection of studies**

Two authors (TF and MV) will independently review studies through two stages: 1) title and abstract screening; 2) full-text screening. If they encounter any inclusion or exclusion discrepancies, the two authors will either resolve them by discussion, or consult a third author who will act as arbitrator. We will exclude duplicate studies.

### **Extraction and management of data**

Using standardized forms, two reviewers will extract data independently from each included study. We will collect the following information: study design, setting, participant characteristics (age, sex, body mass index, homeostasis model assessment- HOMA-, enzymatic levels, intrahepatic triglycerides levels, NAFLD stage, comorbidities), and study eligibility criteria; details about the intervention and comparison, such as calorie restriction, diet composition and duration in dietary intervention and exercise modality, intensity, frequency and duration in exercise protocol; the outcomes assessed and the time they were measured; losses to follow up, exclusions and reasons; the source of funding of the study and the conflicts of interest disclosed by the investigators; the risk of bias assessment for each individual study.

We will resolve disagreements by discussion, and one arbiter will adjudicate unresolved disagreements

### **Assessment of risk of bias in included studies**

Two review authors (TF and MV) will independently assessed the risk of bias using the Cochrane Collaboration's tool for assessing risk of bias, which includes the following items: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other sources of bias. The risk of bias will be classified as high, low or unclear, according to the methods described in Chapter 8 of the Cochrane Handbook for Systematic

Reviews of Interventions (Higgins 2011b). Disagreements will be resolved by discussion and consensus.

### **Measures of treatment effect**

For dichotomous outcomes, we will express the estimate of treatment effect of an intervention as risk ratios (RR) or odds ratios (OR) along with 95% confidence intervals (CI).

For continuous outcomes we will use mean difference and standard deviation (SD) to summarize the data using a 95% CI. Whenever continuous outcomes are measured using different scales, the treatment effect will be expressed as a standardized mean difference (SMD) with 95% CI. For outcomes measure as scores, we will use mean difference and standard deviation. If studies use different scores, the effect will be expressed as standardized mean difference (SMD).

### **Dealing with missing data**

We will write to authors of included trials to request additional data as required. If we do not receive a response from the authors of the studies not reporting primary outcomes, we will analyze available data. We will address the potential impact of missing data on the findings of the review in the discussion using worst- case and best-case scenario.

### **Assessment of heterogeneity**

We will quantify heterogeneity using  $I^2$  test, as it does not inherently depend on the number of studies considered. We will present the  $I^2$  and corresponding 95% CI to gauge the degree of heterogeneity present in the sample.

### **Data synthesis**

Considering that studies will include either a dietary component in addition to exercise, or different types of exercise or diets, we will restrict inclusion to trials compare lifestyle changes to standard care, optimal, conventional care or no intervention.

For any outcomes where data were insufficient to calculate an effect estimate, a narrative synthesis will be presented, describing the studies in terms of direction and size of the effects, and any available measure of precision. For any outcomes where data is available from more than one trial we will conduct a formal quantitative synthesis (meta-analysis) for studies clinically homogeneous using RevMan 5, using the inverse variance method with the random-effects model.

### **Subgroup analysis**

We plan to undertake the following subgroup analyses:

- ☐ Intervention category (diet, exercise or diet plus exercise)
- ☐ NAFLD stages
- ☐ Comorbidities (pure NAFLD versus NAFLD plus comorbidities)
- ☐ Type of exercise (resistance, endurance or combination)
- ☐ Type of diet
- ☐ Exercise intensity (low, moderate or high)

In case we identify significant differences between subgroups (test for interaction  $<0.05$ ) we report the results of individual subgroups separately.

### **Sensitivity analysis**

We will perform sensitivity analysis excluding high risk of bias studies. In cases where the primary analysis effect estimates and the sensitivity analysis effect estimates significantly differ, we will either present the low risk of bias — adjusted sensitivity analysis estimates — or present the primary analysis estimates but downgrading the certainty of the evidence because of risk of bias.

### **Authors' contributions**

TF conceived the protocol. TF drafted the manuscript, and all other authors contributed to it. The corresponding author is the guarantor and declares that all authors meet authorship criteria and that no other authors meeting the criteria have been omitted.

### **Funding statement**

This work was supported by FONDECYT Chile grant number 1191183.

### **References**

#### **Arab 2018**

Juan Pablo Arab, Marco Arrese and Michael Trauner. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. *Annual Review of Pathology: Mechanisms of Diseases* 2018; 13:321-50.

#### **Araújo 2018**

Ana Ruth Araújo, Natalis Rosso, Giorgio Bedogni, Claudio Tiribelli, Stefano Bellentani. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future. *Liver International* 2018; 38(Suppl. 1):47–51.

#### **Chalasani 2018**

Naga Chalasani, Zobair Younossi, Joel E. Lavine, Michael Charlton, Kenneth Cusi, Mary Rinella, Stephen A. Harrison, Elizabeth M. Brunt and Arun J. Sanyal. The Diagnosis and

Management of Nonalcoholic Fatty Liver Disease: Practice Guidance from the American Association for the Study of Liver Diseases. American Association for the Study of Liver Diseases 2018;67(1):328-57.

**Dongiovanni 2016**

Paola Dongiovanni, Claudia Lanti, Patrizia Riso, Luca Valenti. Nutritional therapy for non-alcoholic fatty liver disease. Journal of Nutritional Biochemistry 2016; 29:1-11.

**EASL 2016**

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, Diabetology and Obesity facts 2016;9:65-90.

**Hannah 2015**

William N. Hannah Jr, Stephen A. Harrison. Effect of Weight Loss, Diet, Exercise, and Bariatric Surgery on Nonalcoholic Fatty Liver Disease. Clinical Liver Disease 2015;1-12.

**Katsagoni 2017**

Christina N Katsagoni, Michael Georgoulis, George V Papatheodoridis, Demosthenes B Panagiotakos, Meropi D Kontogianni. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism Clinical and Experimental 2017; 68:119-32.

**Kemp 2008**

Kemp WL, Burns DK, Brown TG. Pathology: The Big Picture. New York: McGraw-Hill, 2008.

**Kenneally 2017**

Susan Kenneally, Joanna H Sier, J Bernadette Moore. Efficacy of dietary and physical activity intervention in non-alcoholic fatty liver disease: a systematic review. BMJ open Gastroenterology 2017;1-12.

**Malaguarnera 2008**

Mariano Malaguarnera, Michelino Di Rosa, Ferdinando Nicoletti, Lucia Malaguarnera. Molecular mechanisms involved in NAFLD progression. Journal of Molecular Medicine 2009;1-18.

**McCarthy 2012**



Erin Marie McCarthy, Mary E. Rinella. The Role of Diet and Nutrient Composition in Nonalcoholic Fatty Liver Disease. *Journal of the academy of nutrition and dietetics* 2012;112(3):401-9.

### **Reisner 2015**

Reisner HM. *Pathology: A Modern Case Study*. New York: McGraw-Hill, 2015.

### **Romero-Gómez 2017**

Manuel Romero-Gómez, Shira Zelber-Sagi, Michael Trenell. Treatment of NAFLD with diet, physical activity and exercise. *Journal of Hepatology* 2017; 67:829-46.

### **Thoma 2012**

Christian Thoma, Christopher P. Day, Michael I. Trenell. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review. *Journal of Hepatology* 2012; 56:255-66.

### **van Der Windt 2018**

Dirk J. van der Windt, Vikas Sud, Hongji Zhang, Allan Tsung, and Hai Huang. The Effects of Physical Exercise on Fatty Liver Disease. *Gene Expression* 2018; 18:89-101.

### **Wong 2013**

Vincent Wai-Sun Wong, Ruth Suk-Mei Chan, Grace Lai-Hung Wong, Bernice, Ho-Ki Cheung, Winnie Chiu-Wing Chu, David Ka-Wai Yeung, Angel Mei-Ling Chim, Jennifer Wing-Yan Lai, Liz Sin Li, Mandy Man-Mei Sea, Francis Ka-Leung Chan, Joseph Jao-Yiu Sung, Jean Woo, Henry Lik-Yuen Chan. Community-based lifestyle modification program for non-alcoholic fatty liver disease: A randomized controlled trial. *Journal of Hepatology*. 2013;59(3):536-42

### **Younossi 2017**

Zobair M. Younossi. Long-Term Outcomes of Nonalcoholic Fatty Liver Disease: From Nonalcoholic Steatohepatitis to Nonalcoholic Steatofibrosis. *Clin Gastroenterol Hepatog*. 2017 Aug;15(8):1144-1147

### **Zou 2018**

Tian-Tian Zoua, Chao Zhangg, Yi-Fan Zhoua, Yi-Jing Hana, Jiao-Jiao Xionga, Xi-Xi Wua Yong-Ping Chena and Ming-Hua Zheng. Lifestyle interventions for patients with

nonalcoholic fatty liver disease: a network meta-analysis. *European Journal of Gastroenterology & Hepatology*. 30(7):747-755.